SLRX Salarius Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLRX

Price (delayed)

$0.501

Market cap

$2.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.84

Enterprise value

-$3.45M

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment ...

Highlights
The EPS has soared by 74% YoY and by 46% from the previous quarter
SLRX's net income has surged by 60% year-on-year and by 30% since the previous quarter
SLRX's equity is down by 49% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://salariuspharma.com
Peers: AMRC AGX KBR

Key stats

What are the main financial stats of SLRX
Market
Shares outstanding
4.31M
Market cap
$2.16M
Enterprise value
-$3.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$12.54M
EBITDA
-$12.53M
Free cash flow
-$12.85M
Per share
EPS
-$3.84
Free cash flow per share
-$3.93
Book value per share
$1.34
Revenue per share
$0
TBVPS
$2.02
Balance sheet
Total assets
$6.59M
Total liabilities
$1.3M
Debt
$289,643
Equity
$5.29M
Working capital
$5.22M
Liquidity
Debt to equity
0.05
Current ratio
5.02
Quick ratio
4.54
Net debt/EBITDA
0.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-135.2%
Return on equity
-198%
Return on invested capital
N/A
Return on capital employed
-237.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SLRX stock price

How has the Salarius Pharmaceuticals stock price performed over time
Intraday
2.24%
1 week
0.2%
1 month
2.92%
1 year
-71.37%
YTD
-22.92%
QTD
-5.22%

Financial performance

How have Salarius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.89M
Net income
-$12.54M
Gross margin
N/A
Net margin
N/A
SLRX's net income has surged by 60% year-on-year and by 30% since the previous quarter
The operating income has soared by 60% YoY and by 30% QoQ

Growth

What is Salarius Pharmaceuticals's growth rate over time

Valuation

What is Salarius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 74% YoY and by 46% from the previous quarter
The P/B is 54% lower than the 5-year quarterly average of 0.8 and 26% lower than the last 4 quarters average of 0.5
SLRX's equity is down by 49% YoY and by 13% QoQ

Efficiency

How efficient is Salarius Pharmaceuticals business performance
SLRX's ROE is down by 43% YoY but it is up by 16% from the previous quarter
The ROA is up by 15% QoQ but it is down by 11% YoY

Dividends

What is SLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLRX.

Financial health

How did Salarius Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 70% YoY and by 44% QoQ
Salarius Pharmaceuticals's total assets has shrunk by 55% YoY and by 22% QoQ
The debt is 95% less than the equity
SLRX's equity is down by 49% YoY and by 13% QoQ
SLRX's debt to equity is down by 38% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.